Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.
Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group. Smith CJ, et al. Among authors: scullard g. J Infect Dis. 2005 Oct 15;192(8):1387-97. doi: 10.1086/466534. Epub 2005 Sep 14. J Infect Dis. 2005. PMID: 16170756
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Group. Sabin CA, et al. Among authors: scullard g. BMJ. 2005 Mar 26;330(7493):695. doi: 10.1136/bmj.38369.669850.8F. Epub 2005 Mar 4. BMJ. 2005. PMID: 15749728 Free PMC article.
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D; UK Collaborative Group on HIV Drug Resistance; UK CHIC Study Group. Phillips AN, et al. Among authors: scullard g. AIDS. 2005 Mar 25;19(5):487-94. doi: 10.1097/01.aids.0000162337.58557.3d. AIDS. 2005. PMID: 15764854
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. Moyle GJ, et al. Among authors: scullard g. AIDS. 2006 Oct 24;20(16):2043-50. doi: 10.1097/01.aids.0000247574.33998.03. AIDS. 2006. PMID: 17053350 Clinical Trial.
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G, Johnson M, Dunn DT, Orkin C, Anderson J, Schwenk A, Leen C, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study Steering Committee. Easterbrook PJ, et al. Among authors: scullard g. HIV Med. 2008 Jan;9(1):47-56. doi: 10.1111/j.1468-1293.2008.00512.x. HIV Med. 2008. PMID: 18199172 Free article.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.
D:A:D Study Group; Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. D:A:D Study Group, et al. Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Lancet. 2008. PMID: 18387667 Free PMC article.
Loss to follow-up in an international, multicentre observational study.
Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. Mocroft A, et al. HIV Med. 2008 May;9(5):261-9. doi: 10.1111/j.1468-1293.2008.00557.x. HIV Med. 2008. PMID: 18400074 Free article.
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group; Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, et al. Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862. Clin Infect Dis. 2008. PMID: 18461712 Free PMC article.
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. Bannister WP, et al. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. doi: 10.1097/QAI.0b013e31817ae5c0. J Acquir Immune Defic Syndr. 2008. PMID: 18545152 Clinical Trial.
102 results